By Jason Napodano, CFA
On September 3, 2013, Pozen Inc. (POZN) entered into a licensing and collaboration agreement with Sanofi-aventis U.S. (SNY) for the commercialization of PA-325/40 and PA-81/40 in the U.S. PA-325/40 and PA-81/40 are Pozen's "safer aspirin" products current under U.S. FDA regulatory review with a PDUFA action date scheduled for January 24, 2014. Pozen has been promising a partnership for its PA franchise for over a year now, and it finally delivered with an impressive catch. Partnering with Sanofi-aventis is Pozen's fourth such impressive partnership based on internally-developed combination products. Prior to the licensing and collaboration agreement yesterday for PA, Pozen has previously licensed its "safer NSAID" drug, Vimovo, to AstraZeneca...
Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: